Novo Nordisk Announces Significant Price Drops for Popular GLP-1 Medications Mike Hollan Key Takeaways Novo Nordisk will set a $675/month US list price (effective January 1, 2027) for Wegovy, Ozempic, and Rybelsus, targeting affordability for high-deductible and coinsurance designs
Semaglutide for Fat Loss | STEP Program Data Semaglutides FDA approval for weight loss and chronic weight management was based on the results of phase-3 trials conducted as a part of an ongoing clinical development program called STEP (Semaglutide Treatment Effect in People with Obesity), sponsored by semaglutide's patent holder Novo Nordisk [13]
Considerable interest exists in identifying effects of these drugs beyond glucose-lowering, possibly resulting in improved macrovascular and microvascular outcomes, including in diabetic kidney disease
Optimal Balance Pharmacy, one of Trava partners, is identified as a 503A sterile compounding pharmacy
Retatrutide becomes the right conversation in 2028, when it's actually available, and specifically for patients who tried tirzepatide with insufficient results or who have severe obesity requiring maximum pharmacological intervention
If youre traveling to a place with warmer climates, you need to keep the medication cool